EMEA-002028-PIP01-16-M01

Key facts

Invented name
Imfinzi
Active substance
durvalumab
Therapeutic area
Oncology
Decision number
P/0256/2019
PIP number
EMEA-002028-PIP01-16-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Intravenous use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel. +46 8553 27591
E-mail: paediatrics@astrazeneca.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating